Compare COHU & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COHU | NTLA |
|---|---|---|
| Founded | 1947 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.7B |
| IPO Year | 1994 | 2016 |
| Metric | COHU | NTLA |
|---|---|---|
| Price | $47.68 | $10.85 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 23 |
| Target Price | ★ $40.50 | $20.02 |
| AVG Volume (30 Days) | 1.0M | ★ 4.3M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 27.43 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $452,956,000.00 | $67,671,000.00 |
| Revenue This Year | $14.38 | N/A |
| Revenue Next Year | $19.12 | $62.75 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 12.74 | ★ 16.92 |
| 52 Week Low | $17.80 | $7.95 |
| 52 Week High | $74.60 | $28.24 |
| Indicator | COHU | NTLA |
|---|---|---|
| Relative Strength Index (RSI) | 38.08 | 31.20 |
| Support Level | $43.64 | $8.59 |
| Resistance Level | $52.43 | $15.52 |
| Average True Range (ATR) | 3.54 | 0.79 |
| MACD | -0.88 | -0.42 |
| Stochastic Oscillator | 6.42 | 3.06 |
Cohu Inc is a supplier of semiconductor test and inspection handlers, micro-electro-mechanical system (MEMS) test modules, test contactors, and thermal sub-systems used by semiconductor manufacturers and test subcontractors. The company's products include Semiconductor ATE (Automated Test Equipment), Semiconductor Handlers, Interface Products such as test contactors, probe heads, and probe pins, Spares and Kits, Bare Board PCB Test Systems, and services. It has one reportable segment, Semiconductor Test and Inspection Equipment (Semiconductor Test & Inspection). Geographically, the company generates maximum revenue from the Philippines, followed by Taiwan, China, Malaysia, the United States, Singapore, and the Rest of the world.
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.